A REMS by any Other Name
This article was originally published in RPM Report
A new prescription drug for treatment of varicose veins clears FDA. The only dispute in the review: how to handle a remote but real risk of anaphylaxis. A REMS? Not this time…
You may also be interested in...
Making a Good First Impression: Launch Messages in an Era of REMS
When FDA took the unusual step of reprimanding a clinical investigator for promoting a newly approved botulinum toxin brand, the agency stressed its over-riding concern about the "first impression" of a new product in marketing messages Commercial sponsors should pay attention: just ask King.
FDAAA Impact (Year Two): More of Everything
The second year of the FDAAA-era is over, and FDA is using its new drug safety tools (Risk Evaluation & Mitigation Strategies and mandatory post-marketing studies) more often. Not only are more drugs requiring REMS and mandatory trials, the burden of those programs is increasing.
Dendreon and InterMune: Do They Mean Anything for the Regulatory Climate at FDA?
Provenge and pirfenidone were two of the most closely watched pending applications at FDA. The agency's decision on the two therapies may offer some insight into the current regulatory climate.